

EXPRESS MAIL NO. EV741777646US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Davin C. Dillon et al.

Application No.

10/010,742

Filed

November 30, 2001

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF BREAST CANCER

Art Unit

: 1637

Docket No.

: 210121.491C7

Date

: March 14, 2006

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

THIRD SUPPLMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Supplemental Information Disclosure Statement. Copies of all cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Third Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Third Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Julie A. Urvater, Ph.D., Patent Agent

Registration No. 50,461

JAU:ljt

Enclosures:

Information Disclosure Statement Cited References (16)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\756642

Sheet 1 of 2 MAIL NO. EV741777646US APPLICATION NO. ATTY. DOCKET NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 210121.491C7 10/010.742 APPLICANTS THIRD SUPPLEMENTAL Davin C. Dillon et al. ATION DISCLOSURE STATEMENT (Use several sheets if necessary) FILING DATE **GROUP ART UNIT** November 30, 2001 1637. U.S. PATENT DOCUMENTS FILING DATE *EXAMINER DOCUMENT NUMBER CLASS SUBCLASS DATE IF APPROPRIATE INITIAL AA AΒ FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY NUMBER YES 01/07/99 **WIPO** WO 99/00408 AC WO 99/25877 05/27/99 **WIPO** AD WO 00/12758 03/09/00 **WIPO** WO 00/61756 10/19/00 WIPO ΑF WO 01/40269 06/07/01 **WIPO** AG OTHER ART (Including Author, Title, Date, Pertinent Pages. Etc.) EMBL Database, Accession No. AX317983, December 14, 2001. ΑH EMBL Database, Accession No. CQ421094, January 28, 2004. ΑI GenBank Database, Accession No. AF100759, July 8, 1999. ΑJ Genseg Database (Derwent), Accession No. AAD09946, September 12, 2001. ΑK Genseg Database (Derwent), Accession No. AAL13663, December 7, 2001. AL Genseg Database (Derwent), Accession No. AAW92654, April 30, 1999. AMHara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8α in a mast cell-derived interleukin-4-dependent cell line," Blood 84(1):189-199, July 1, 1994. Hedblom and Kirkness, "A novel class of GABAA receptor subunit in tissues of the

reproductive system," The Journal of Biological Chemistry 272(24):15346-15350, June 13, 1997. Porter-Jordan and Lippman, "Overview of the biologic markers of breast cancer," Breast ΑP Cancer 8(1):73-100, February 1994. DATE CONSIDERED

* EXAMINER:

EXAMINER

ΑO

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPAR PATENT AN THIRD S

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

THIRD SUPPLEMENTAL ATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

_	Silect <u>1</u> 01 <u>1</u> .
ATTY. DOCKET NO.	APPLICATION NO.
210121.491C7	10/010,742
APPLICANTS	
Davin C. Dillon et al.	
FILING DATE	GROUP ART UNIT
November 20, 2001	1637

			U.S.	PATENT DOCUMENTS			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB		- "				
			FOREI	GN PATENT DOCUMENTS			

	DOCUMENT	DATE COUNTRY	COUNTRY	TRANSLATION	
 <u> </u>	NUMBER	DATE	COUNTRY	YES	NO
AC				- · -	
AD	-				
AE					_
AF					
AG					

OTHER ART (Including Author. Title, Date, Pertinent Pages, Etc.)

АН	subtraction and microarray," <i>Proceedings of the American Association for Cancer Research</i> 40: 319, Abstract #2115, March 1999.
Al	Xu, J. et al., "Identification of Differentially Expressed Genes in Human Prostate Cancer Using Subtraction and Microarray," <i>Cancer Research</i> 60: 1677-1682, March 15, 2000.
ΑJ	
AK	
AL	
АМ	
AN	
AO	

EXAMINER

DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).